» Articles » PMID: 37500993

Nutritional and Metabolic Factors in Amyotrophic Lateral Sclerosis

Overview
Journal Nat Rev Neurol
Specialty Neurology
Date 2023 Jul 27
PMID 37500993
Authors
Affiliations
Soon will be listed here.
Abstract

Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disease that is classically thought to impact the motor system. Over the past 20 years, research has started to consider the contribution of non-motor symptoms and features of the disease, and how they might affect ALS prognosis. Of the non-motor features of the disease, nutritional status (for example, malnutrition) and metabolic balance (for example, weight loss and hypermetabolism) have been consistently shown to contribute to more rapid disease progression and/or earlier death. Several complex cellular changes observed in ALS, including mitochondrial dysfunction, are also starting to be shown to contribute to bioenergetic failure. The resulting energy depletion in high energy demanding neurons makes them sensitive to apoptosis. Given that nutritional and metabolic stressors at the whole-body and cellular level can impact the capacity to maintain optimal function, these factors present avenues through which we can identify novel targets for treatment in ALS. Several clinical trials are now underway evaluating the effectiveness of modifying energy balance in ALS, making this article timely in reviewing the evidence base for metabolic and nutritional interventions.

Citing Articles

An open-label Phase 2a study to assess the safety and tolerability of trimetazidine in patients with amyotrophic lateral sclerosis.

van Eijk R, Steyn F, Janse van Mantgem M, Schmidt A, Meyjes M, Allen S Brain Commun. 2025; 7(1):fcaf063.

PMID: 40008327 PMC: 11851067. DOI: 10.1093/braincomms/fcaf063.


Actual needs of patients with amyotrophic lateral sclerosis: a qualitative study from Wuhan, China.

Zeng L, Yang F, Xu D, Zhou J, Qiao G, Wu M BMC Palliat Care. 2025; 24(1):50.

PMID: 39987111 PMC: 11846365. DOI: 10.1186/s12904-025-01684-8.


Tofersen and other antisense oligonucleotides in ALS.

Ludolph A, Wiesenfarth M Ther Adv Neurol Disord. 2025; 18():17562864251313915.

PMID: 39845577 PMC: 11752197. DOI: 10.1177/17562864251313915.


Data Report: Educational pathway addressing food and nutrition in amyotrophic lateral sclerosis on the AVASUS platform.

Coutinho K, Fernandes F, Medeiros K, Coutinho K, Dias A, Valentim R Front Digit Health. 2025; 6():1476293.

PMID: 39834841 PMC: 11743485. DOI: 10.3389/fdgth.2024.1476293.


Nutritional and Microbiota-Based Approaches in Amyotrophic Lateral Sclerosis: From Prevention to Treatment.

Cuffaro F, Lamminpaa I, Niccolai E, Amedei A Nutrients. 2025; 17(1.

PMID: 39796536 PMC: 11722677. DOI: 10.3390/nu17010102.


References
1.
Hardiman O, Al-Chalabi A, Chio A, Corr E, Logroscino G, Robberecht W . Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017; 3:17071. DOI: 10.1038/nrdp.2017.71. View

2.
Van Damme P, Robberecht W, Van Den Bosch L . Modelling amyotrophic lateral sclerosis: progress and possibilities. Dis Model Mech. 2017; 10(5):537-549. PMC: 5451175. DOI: 10.1242/dmm.029058. View

3.
Renton A, Chio A, Traynor B . State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2013; 17(1):17-23. PMC: 4544832. DOI: 10.1038/nn.3584. View

4.
Renton A, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs J . A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011; 72(2):257-68. PMC: 3200438. DOI: 10.1016/j.neuron.2011.09.010. View

5.
Muller K, Brenner D, Weydt P, Meyer T, Grehl T, Petri S . Comprehensive analysis of the mutation spectrum in 301 German ALS families. J Neurol Neurosurg Psychiatry. 2018; 89(8):817-827. DOI: 10.1136/jnnp-2017-317611. View